Pfizer 2014 Annual Report Download - page 75

Download and view the complete annual report

Please find page 75 of the 2014 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

PFIZER ANNUAL REVIEW 2014 www.pzer.com/annual 75
ANNUAL REVIEW 2014
ENVIRONMENT
LIFECYCLE ASSESSMENT CONFIRMS
REDUCED IMPACT OF SMALLER TABLET
IN BLISTER PACK
Our World > Environment
With the help of Quantis, globally recognized experts in lifecycle
assessment consulting, we completed a full lifecycle assessment of
Pzer’s current version of Atorvastatin, also known as Lipitor.® The
lifecycle assessment evaluated potential ecosystem quality impact,
climate change impact, resource consumption and water usage of two
tablet sizes.
Our lifecycle assessment of the smaller tablet in blister packs
(available in many markets) identied the following carbon footprint
reductions when compared to our larger tablet:*
• Less materials required (42% reduction in non-active
pharmaceutical ingredient raw material footprint)
• Less to ship (36% reduction in delivery footprint)
• Less packaging required (11% reduction in packaging
material footprint)
In addition, we evaluated our latest manufacturing process
improvements, which incorporate the principles of “green chemistry,”
against our original manufacturing process. Our latest innovative
manufacturing process uses enzymes (bio-catalysts), water as a
solvent and room temperature reactions. These changes reduced the
carbon footprint of the raw materials used in our current Atorvastatin
active pharmaceutical ingredient (API) manufacturing process by half
when compared to our original manufacturing process.
Through the implementation of improved chemistry, introducing
a smaller tablet, and reducing packaging, Pzer has been able
to reduce this product’s carbon footprint and other environmental
indicators as compared to when we rst began making the product.
*The API footprint is the same for both tablet sizes; these reductions are specic to the
other aspects of the smaller tablet.
1.6
MILLION METRIC TONS CO2eq4
GREENHOUSE GAS EMISSIONS
TOTAL SCOPE 1 AND 2 GHG EMISSIONS IN
2014 WERE 5% LOWER THAN IN 2013.
14
MILLION CUBIC METERS4
WATER WITHDRAWAL
TOTAL WATER WITHDRAWAL
EXCLUDING NON-CONTACT COOLING
WATER IN 2014 WAS 9%
LOWER THAN IN 2013.
106
THOUSAND METRIC TONS4
WASTE DISPOSED
TOTAL HAZARDOUS AND
NON-HAZARDOUS WASTE
DISPOSED IN 2014
WAS UNCHANGED FROM 2013.